Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

cent body surface area (BSA), a minimum PASI score of 12 and who were candidates for phototherapy or systemic therapy. Patients received either REMICADE 5 mg/kg or placebo administered at weeks 0, 2 and 6, followed by maintenance treatment every 8 weeks. The REMICADE group continued on maintenance treatments every 8 weeks. Patients in the placebo group were crossed over at week 24 to receive REMICADE 5 mg/kg at weeks 24, 26 and 30, then every 8 weeks through week 46.

In EXPRESS, through week 24, adverse events (AEs) occurred at a higher incidence in the REMICADE group (82 percent) compared with the placebo group (71 percent). The only clinically significant laboratory abnormalities that occurred more frequently in the REMICADE group compared with the placebo group were elevated liver enzyme tests. There were more serious AEs (6 percent), including one fatal infection, in the REMICADE group than in the placebo group (3 percent). AEs observed were generally consistent with those described in the prescribing information, including information regarding serious infections. Please see "Important Safety Information" below.

About EXPRESS II

EXPRESS II was a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of REMICADE in 835 adult patients with chronic, stable plaque psoriasis involving at least 10 percent BSA, a minimum PASI score of 12 and who were candidates for phototherapy or systemic therapy. Patients were randomized to induction doses of REMICADE 3 mg/kg or 5 mg/kg or placebo at weeks 0, 2 and 6. Patients in the active induction treatment groups were randomized again at week 14 to receive either scheduled or "as-needed" maintenance treatment at the same dose administered during the induction phase. Patients in the placebo group were crossed over at week 16 to receive REMICADE 5 mg/kg at weeks 16, 18 and 22, then every 8 weeks through week 46.

In EXPRESS II, through week 14 (th
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Boehringer Ingelheim will contribute to advancing ... American Thoracic Society International Conference (ATS 2013) in ... – 22. Data will highlight research ... of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® ... compounds for asthma, idiopathic pulmonary fibrosis (IPF) and ...
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
(Date:5/18/2013)... Morro Bay, CA (PRWEB) May 18, 2013 ... salon , has recently completed a stylish renovation that ... and advanced specialties. , From the ground up, this ... been improved with fresh flooring, soothing colors and comfortable ... have been installed, including an Apilus epilator machine. ...
(Date:5/18/2013)... Spectrum Surgical Instruments will attend the ... Austin, TX where thousands of GI nursing professionals ... , Spectrum Surgical/STERIS will feature its flexible ... capabilities and certified pre-owned equipment. Attendees will also ... instrument care of flexible endoscopes. , Visit ...
(Date:5/18/2013)... Miami, FL (PRWEB) May 18, 2013 ... accessories, is now offering its customers an attractive 25% ... Corkscrew. , Customers can now purchase this ... safe and secure online transactional process. The online store ... from the date of order placement. , A ...
(Date:5/18/2013)... UT (PRWEB) May 18, 2013 Medical device ... orders for its much anticipated mobility aid with its namesake, ... create a hands-free crutch alternative that injured individuals ... broken ankle, for example, can remain active and walk during ... is using its reservation system to ensure those who need ...
(Date:5/17/2013)... 18, 2013. Chronic trauma can inflict lasting damage to ... studies of people with post-traumatic stress disorder, or PTSD, ... in response to stressful tasks, such as recalling a ... threatening face. Now, researchers at NYU School of Medicine ... the brains of combat veterans with PTSD in the ...
Breaking Medicine News(10 mins):Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Now Save 25% on Franmara Dynamo Electric Wine Bottle Opener at Wine World Accessories 2Health News:FlexLeg Begins Offering New Mobility Aid 2Health News:For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests 2
... Jan. 28, 2009 Physical therapists at UT Southwestern ... people recovering from neurological injuries such as strokes and traumatic ... repeatedly practice movements needed to regain arm strength and movement. ... sites testing how the Armeo device, with its virtual environment ...
... with AsthmaWASHINGTON, Jan. 28 St. Louis, MO, is ranked ... to live with asthma in the U.S. (1) - according ... conducted the study. This ranking was determined based on an ... U.S. metro areas. (1) St. Louis was ranked No.1 this ...
... Relocated to Adjacent Proton Site in Warrenville CHICAGO, ... Illinois state approval on its plans to build ... in Warrenville. The Illinois Health Facilities Planning Board ... the project,s Certificate of Need application during today,s ...
... disease that,s harder to control, study says , , TUESDAY, ... of tuberculosis patients in the United States who say ... and difficult to treat than other TB patients, a ... patients aged 15 or older. Of those patients, 28,650 ...
... and Republican Party on Wrong TrackSACRAMENTO, Calif., Jan. 27 ... claimed that the Medicaid Family Planning State Option, a ... millions of women, would cost hundreds of millions of ... misleading attacks and partisan politics, was dropped from the ...
... ReportedCARLSBAD, Calif., Jan. 27 Jenny Craig, Inc. ... management, today announced a voluntary recall of its ... (UPC Code 655447009347) for U.S and P.R. distribution ... MAY2409BLO, MAY2509BLO, MAY2509ALO, MAY2609ALO, & MAY2609BLO, because the ...
Cached Medicine News:Health News:Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury 2Health News:Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury 3Health News:St. Louis Named Top Asthma Capital for 2009 2Health News:St. Louis Named Top Asthma Capital for 2009 3Health News:St. Louis Named Top Asthma Capital for 2009 4Health News:St. Louis Named Top Asthma Capital for 2009 5Health News:St. Louis Named Top Asthma Capital for 2009 6Health News:Central DuPage Hospital Wins State Approval to Build Cancer Center 2Health News:Central DuPage Hospital Wins State Approval to Build Cancer Center 3Health News:Substance Abuse Hinders TB Treatment 2Health News:Family Planning Provision Wrongfully Removed From Economic Stimulus Package 2Health News:Jenny Craig Announces Nationwide Voluntary Recall of Jenny's Cuisine(R) Anytime Peanut Butter Flavor Nutritional Bars Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... exchange in endourological procedures. The increased inner ... utilization of an extra heavy duty mandril ... flexible tip. The proximal end of this ... wire guide manufactured by Cook®. Supplied sterile ...
Medicine Products: